ArticleFrontiers in oncology2026
Spatial distribution and prognostic value of tumor-associated macrophages in head and neck squamous cell carcinomas.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tumor-associated macrophages (TAMs) belong to the most frequent immune cells in the tumor microenvironment of head and neck squamous cell carcinomas (HNSCC). They can undergo an anti- or pro-tumoral polarization, the latter often referred to as M2-like activation. Because existing data are either not consistent, not well-connected to clinicopathological parameters or lack a detailed spatial distribution, we aimed to get more insight into the relevance of this immune cell population and their activation status. Methods: This study analyzed the spatial distribution and prognostic value of CD68+TAMs and CD68+CD163+M2-like TAMs in different tumor compartments and tumor-distant stromal areas, in 85 treatment-naïve HNSCC. Various clinicopathological features were considered, such as major tumor sites, stage, T-stage, nodal status and p16-status. TAM and M2-like TAM densities were analyzed using multicolor immunofluorescence stainings followed by an objective tissue cytometry-based quantification at the single-cell level in whole tissue sections and subsequent uni- and multivariate survival analyses. Results: Whereas we observed higher TAM and M2-like TAM densities in p16-negative HNSCC specimens, densities of M2-like TAMs were highest in the tumor-near stroma of advanced nodal-positive p16-negative HNSCC compared to tumor cell nests and tumor-distant stroma, particularly in younger and male patients and patients with hypopharynx carcinomas. Moreover, higher infiltration of M2-like TAMs turned out to be an independent prognostic factor of poorer survival even exceeding the impact of the p16-status and the tumor site. Discussion: In summary, our data provide a strong rationale to target M2-like TAMs to improve success of immune-modulatory treatments and survival of patients suffering from p16-negative HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.